Prism TPO Expands Pharma Partnerships, Earning Recognition from 17 Manufacturers Across 36 Oncology Drug Contracts

Prism TPO, the first transparent purchasing organization for independent oncology practices, announced today that it has been recognized by 17 leading pharmaceutical manufacturers as an official aggregator spanning 36 oncology drug contracts. This milestone reflects Prism’s growing role in building a more efficient and accountable marketplace for life-saving cancer treatments.

By combining scale with execution, Prism gives manufacturers a direct pathway to community-based oncology providers while enabling practices to access competitive, sustainable drug pricing. The result is a model that fosters efficiency, trust, and measurable value across the oncology ecosystem.

“Pharma companies want partners who bring scale, execution, and accountability,” said Brian Wydra, Vice President of Pharmaceutical Partnerships. “We’re building a network that meets those expectations—while delivering transparent, data-driven value to manufacturers and the independent oncology providers they support.”

Recognition from leading pharmaceutical partners underscores Prism’s unique approach. Through streamlined contracting and rebate management, the company simplifies complex processes and delivers visibility across the supply chain—positioning Prism as a strategic ally in strengthening the economics of independent oncology practices.

As Chief Medical Officer and President of Columbus Oncology & Hematology, overseeing three cancer centers in Central Ohio, Dr. Joseph Hofmeister has seen firsthand how transparent pharma partnerships help sustain both clinical excellence and financial stability for independent providers.

“Prism TPO has enhanced how we engage with the pharmaceutical industry,” said Dr. Hofmeister. “Through their network of trusted partnerships, we have increased direct access to competitive, transparent pricing and clearly defined savings opportunities. This collaboration not only strengthens our ability to deliver high-quality care, it ensures we can do so in a financially sustainable way—a win for both our practice and our patients."

Prism’s collaborative model continues to deliver measurable growth across oncology portfolios. In multiple myeloma, practices participating under a new manufacturer agreement saw an 82% increase in therapy utilization during the first quarter, driven by new adoption across three independent practices not previously utilizing the product. Continued engagement projects a 212% increase by the end of the second quarter—reflecting strong alignment between manufacturers and community-based providers.

These results illustrate the performance impact Prism and its member network deliver through the company’s innovative approach to performance monitoring, real-time data insights, and the collective expertise of its Pharmacy, Therapeutics & Economics (PTE) Committee. Together, these mechanisms enable Prism and its members to act as one—driving shared accountability, alignment, and patient impact.

Prism TPO will participate in the Association for Value-Based Cancer Care Summit taking place October 22-24 in New York, NY, where Founder and CEO Tesh Khullar will be a featured panelist. For more information or to connect with the team, visit PrismTPO.com.

Media Contact
Prism TPO
press@prismtpo.com